menu
    • menu

    Company profile for Imvax

    NEW Drugs in Dev: 1
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Imvax was founded by a neurosurgeon striving to change the landscape of treatment for GBM patients to extend both the duration and quality of their lives. The Imvax approach is “antigen-agnostic” and our proprietary methodology provides the immune system with the patient’s own unique multi-antigen tumor profile, telling the body where and what to fight. The resulting systemic, long-lasting immune response specifically ta...
    Imvax was founded by a neurosurgeon striving to change the landscape of treatment for GBM patients to extend both the duration and quality of their lives. The Imvax approach is “antigen-agnostic” and our proprietary methodology provides the immune system with the patient’s own unique multi-antigen tumor profile, telling the body where and what to fight. The resulting systemic, long-lasting immune response specifically targets the tumor’s entire antigen profile, while simultaneously nullifying its immune-silencing ability.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImvaxUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    601 Walnut St, Suite 440 W Philadelphia, PA 19106
    Telephone
    Telephone
    267-900-4110
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.imvax.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/imvax-inc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASCO GU

    ASCO GU

    Not Confirmed

    envelop Contact Supplier

    ASCO GU

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Imvax Submits Glioblastoma Data To FDA Showing 6-Month Survival
    Imvax Submits Glioblastoma Data To FDA Showing 6-Month Survival

    02 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-02/imvax-announces-positive-top-line-data-from-phase-2b-clinical-trial-of-igv-001-in-newly-diagnosed-gb

    PHARMIWEB
    02 Dec 2025
    Share Share
    Imvax to Present Safety Data on IGV-001 at 2024 SNO Annual Meeting
    Imvax to Present Safety Data on IGV-001 at 2024 SNO Annual Meeting

    11 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241111079467/en

    BUSINESSWIRE
    11 Nov 2024
    Share Share
    Imvax Completes IGV-001 Phase 2b Enrollment, Funding Round
    Imvax Completes IGV-001 Phase 2b Enrollment, Funding Round

    21 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240521075968/en

    BUSINESSWIRE
    21 May 2024
    Share Share
    Imvax Presents New Data at 2023 SNO Annual Meeting Supporting its IGV-001
    Imvax Presents New Data at 2023 SNO Annual Meeting Supporting its IGV-001

    20 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231120684700/en

    BUSINESSWIRE
    20 Nov 2023
    Share Share
    Imvax to Present New Data on Lead Program, IGV-001, at 2023 SNO Annual Meeting
    Imvax to Present New Data on Lead Program, IGV-001, at 2023 SNO Annual Meeting

    10 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231110515204/en

    BUSINESSWIRE
    10 Nov 2023
    Share Share
    Imvax Provides Corporate Update
    Imvax Provides Corporate Update

    06 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230906874341/en

    BUSINESSWIRE
    06 Sep 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search